EMAC LIMITED

Risk Rating: MEDIUM
The company is active, has been on the register since 1996, and is currently up to date with its accounts and confirmation statement filings. However, the available dataset does not include actual financial figures—such as turnover, profit, net assets, cash, or debt levels—so a robust solvency and liquidity assessment cannot be completed. The recent resignation of two directors and an unclear PSC structure add enough uncertainty to warrant a cautious MEDIUM rating rather than LOW.

Key Concerns

1. No Financial Data Provided
   The most significant issue is the absence of financial statement figures. Without a balance sheet, profit and loss account, or cash-flow information, it is not possible to determine whether the company has positive net assets, sufficient working capital, or an appropriate level of gearing. The filing status is compliant, but that does not itself demonstrate solvency.

2. Recent Director Departures
   Two directors—Xxxxxx Xxxxxxxxname shown to subscribers and Xxxxxx Xxxxxxxxname shown to subscribers—are shown as resigning in April and May 2026. There is no explanation provided for these departures. While director changes are not uncommon, the clustering of resignations can sometimes signal strategic disagreement, restructuring, or governance tension. This should be investigated.

3. Unclear or Duplicated PSC Information
   The persons with significant control register lists both The Innovation Group Limited and Ingleby (1879) Limited as owning more than 75% of shares and voting rights. Ingleby (1879) Limited appears twice. As presented, this is not fully clear and may reflect a data extraction duplication or a group restructure. The immediate and ultimate ownership relationship needs to be confirmed, as this affects counterparty and group-support risk.

Positive Indicators

• Long Operating History
  The company was incorporated in 1996 and remains active. A roughly 30-year track record suggests the business has survived multiple economic cycles and is likely established in its market.

• On-Time Regulatory Filings
  The latest accounts and confirmation statement are not shown as overdue. This indicates basic compliance with Companies House obligations and reduces the immediate regulatory-risk concern.

• No Insolvency or Formal Proceedings
  The company is not in liquidation, administration, or receivership. No filing-related penalties or strike-off actions are evident from the data supplied.

Due Diligence Notes

• Obtain and review the latest full annual accounts filed at Companies House. Key items to examine include net current assets, shareholder funds, debt maturity profile, related-party balances, and any auditor qualifications.
• Clarify the exact nature of the business activity under SIC 96090. This code is broad and could cover a wide range of operating models, so revenue sources and customer concentration should be understood.
• Confirm the current group structure, including the relationship between The Innovation Group Limited, Ingleby (1879) Limited, and EMAC Limited. Establish whether the company receives group financial support, guarantees, or intra-group funding.
• Investigate the director resignations in 2026. Confirm whether replacements have been appointed and whether any governance or control concerns were raised.
• Search the Companies House charges register to identify any secured borrowings or contingent liabilities not visible in the summary data.
• Consider searching director conduct records to confirm there are no disqualifications or unresolved actions involving any current or former officers.

Executive Summary
EMAC Limited appears administratively compliant and has a long operating history, with no evidence of insolvency proceedings. However, the lack of financial statement data prevents a meaningful conclusion on solvency or liquidity, and the recent director departures plus unclear PSC information require further investigation. Overall, the company carries a MEDIUM risk rating based primarily on information gaps rather than identified adverse findings.

Names of the people mentioned are shown to subscribers. See subscription